NanoViricides (NYSE: NNVC) is a pre-clinical biotech company that has utilized its patented platform technology to rapidly create anti-viral drug candidates. The company has conducted tests on more than 6,000 animals infected with various strains of influenza, HIV, dengue/dengue hemorrhagic fever, Ebola, rabies, adenovirus of the eye as well as herpes infections of the skin and the eye without evidence of resistance, side effects or toxicity. Treatments for various forms of acute herpes infections are now being advanced through the pre-clinical process toward human trials. For more information, visit the company’s website at www.nanoviricides.com